(CercleFinance.com) – Sanofi announces that the AMEERA-3 phase II clinical trial evaluating amcenestrant did not meet its primary endpoint, namely improvement in progression-free survival, according to a centralized evaluation independent.
The trial compared amcenestrant as monotherapy with an endocrine treatment chosen by the doctor, in patients with advanced or metastatic ER+/HER2- breast cancer, which progressed during or after hormone treatments.
No new safety signals were identified and the safety profile of amcenestrant in this trial was consistent with that observed in previous studies. Ongoing trials, including AMEERA-5 and AMEERA-6, are continuing as planned.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
